BRAIN CANCER

During a live event, Jan Drappatz, MD, and participants discussed which patients with glioma should receive IDH inhibitors and what next steps could identify who will benefit.

Discover groundbreaking advancements in glioblastoma treatment, including FDA approvals and innovative therapies reshaping neuro-oncology in 2025.

Interim results reveal RAD 101's promising potential in accurately diagnosing brain metastases, enhancing treatment decisions for patients.

Erdafitinib shows promising efficacy and manageable safety in treating recurrent gliomas with F3T3 gene fusions, according to recent trial findings.

During a live event, Jan Drappatz, MD, surveyed participants on the rationale for their choice of treatment for a 39-year-old patient with grade 2 astrocytoma.

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative biomarker-driven therapies.

New phase 2 trial results reveal safusidenib's potential to significantly improve outcomes for patients with IDH1-mutant gliomas, offering hope for durable responses.

New trial data reveals IGV-001 enhances overall survival in glioblastoma patients, marking a potential breakthrough in treatment options.

The FDA fast-tracks zotiraciclib for recurrent high-grade gliomas, offering hope for patients with IDH mutations and expanding treatment options.

Vorasidenib significantly reduces tumor growth rates in grade 2 glioma patients, improving progression-free survival and time to next intervention.

Naxitamab combined with GM-CSF shows promising results in treating high-risk neuroblastoma, achieving high response rates and manageable safety profiles.

A phase 1 study reveals that sequential CR7-GD2 CAR T-cell therapy administration is better tolerated in pediatric CNS tumor patients than concurrent methods.

Tovorafenib shows promising long-term efficacy for pediatric low-grade glioma, with significant treatment-free intervals and manageable safety profile.

New findings from the TEM-GBM study reveal promising survival rates for patients with glioblastoma treated with the experimental gene therapy Temferon.

Eflornithine combined with lomustine shows promising survival benefits for patients with recurrent IDH-mutant grade 3 astrocytoma in recent trials.

The FDA approves selumetinib for adults with neurofibromatosis type 1, offering new hope for treating inoperable plexiform neurofibromas.

Tinostamustine receives FDA orphan drug designation, promising new hope for glioblastoma treatment with innovative dual-action mechanism.

Vorasidenib shows significant long-term benefits for IDH-mutant glioma patients, enhancing survival and delaying treatment needs post-surgery.

Exosome-based therapy for glioblastoma receives FDA orphan drug designation, promising targeted treatment and improved delivery methods for cancer care.

The FDA fast tracks MT-125, a promising new treatment for glioblastoma, enhancing patient care and expediting drug development.

A clinical study highlights the safety and feasibility of ClearPoint Prism Neuro Laser Therapy for treating brain tumors, showcasing innovative minimally invasive techniques.

FDA grants orphan drug designation to cintredekin besudotox, offering new hope for glioblastoma treatment with targeted delivery methods.

FDA designates AMXT 1501 and DFMO as an orphan drug for neuroblastoma, aiming to enhance treatment outcomes for pediatric patients.

Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent patient needs.

The FDA approves selumetinib for young patients with neurofibromatosis type 1, offering hope for effective treatment of inoperable tumors.